tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Eupraxia Pharmaceuticals’ EP-104GI: A Promising Annual Treatment for Eosinophilic Esophagitis with Significant Market Potential
RatingsEupraxia Pharmaceuticals’ EP-104GI: A Promising Annual Treatment for Eosinophilic Esophagitis with Significant Market Potential
7d ago
EPRX
Eupraxia Pharmaceuticals Reports Promising 1-Year Results for EoE Treatment
PremiumCompany Announcements
Eupraxia Pharmaceuticals Reports Promising 1-Year Results for EoE Treatment
7d ago
EPRX
Eupraxia Pharmaceuticals announces data from RESOLVE trial in EoE
PremiumThe Fly
Eupraxia Pharmaceuticals announces data from RESOLVE trial in EoE
7d ago
EPRX
Celldex data supports positive Eupraxia thesis, says H.C. Wainwright
PremiumThe Fly
Celldex data supports positive Eupraxia thesis, says H.C. Wainwright
20d ago
CLDX
EPRX
Eupraxia Pharmaceuticals’ EP-104GI: A Promising Comprehensive Treatment for Eosinophilic Esophagitis with Strong Buy Recommendation
PremiumRatings
Eupraxia Pharmaceuticals’ EP-104GI: A Promising Comprehensive Treatment for Eosinophilic Esophagitis with Strong Buy Recommendation
20d ago
EPRX
Eupraxia Pharmaceuticals: Promising Potential in EoE Treatment with EP-104GI and Strong Financial Position
PremiumRatingsEupraxia Pharmaceuticals: Promising Potential in EoE Treatment with EP-104GI and Strong Financial Position
27d ago
EPRX
Eupraxia Pharmaceuticals Advances EoE Treatment Trials Amid Financial Challenges
Premium
Company Announcements
Eupraxia Pharmaceuticals Advances EoE Treatment Trials Amid Financial Challenges
28d ago
EPRX
Eupraxia Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
Premium
The Fly
Eupraxia Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
2M ago
EPRX
Eupraxia Pharmaceuticals to Present at Key Investor Conferences
PremiumCompany Announcements
Eupraxia Pharmaceuticals to Present at Key Investor Conferences
2M ago
EPRX
Promising Developments in Eupraxia Pharmaceuticals’ EoE Trial Justify Buy Rating
PremiumRatings
Promising Developments in Eupraxia Pharmaceuticals’ EoE Trial Justify Buy Rating
2M ago
EPRX
Eupraxia Pharmaceuticals Advances RESOLVE Trial with First Patient Dosed in Phase 2b
PremiumCompany Announcements
Eupraxia Pharmaceuticals Advances RESOLVE Trial with First Patient Dosed in Phase 2b
2M ago
6K
EPRX
Eupraxia Pharma doses first patient in Phase 2b trial of EP-104GI in esophagitis
PremiumThe Fly
Eupraxia Pharma doses first patient in Phase 2b trial of EP-104GI in esophagitis
2M ago
EPRX
Promising Future for Eupraxia Pharmaceuticals: Buy Rating Affirmed on Strong EP-104GI Trial Results
PremiumRatingsPromising Future for Eupraxia Pharmaceuticals: Buy Rating Affirmed on Strong EP-104GI Trial Results
3M ago
EPRX
Eupraxia Pharmaceuticals initiated with a Buy at H.C. Wainwright
Premium
The Fly
Eupraxia Pharmaceuticals initiated with a Buy at H.C. Wainwright
3M ago
EPRX
Eupraxia Pharmaceuticals initiated with a Speculative Buy at Canaccord
Premium
The Fly
Eupraxia Pharmaceuticals initiated with a Speculative Buy at Canaccord
3M ago
EPRX
Eupraxia Pharmaceuticals Strengthens Governance with Board Elections and Strategic Approvals
PremiumCompany Announcements
Eupraxia Pharmaceuticals Strengthens Governance with Board Elections and Strategic Approvals
3M ago
EPRX
Eupraxia Pharmaceuticals to Host Virtual Event on EoE Treatment Study
PremiumCompany Announcements
Eupraxia Pharmaceuticals to Host Virtual Event on EoE Treatment Study
4M ago
6K
EPRX
Eupraxia Pharmaceuticals reports Q1 net loss $6.8M vs. $6.2M last year
PremiumThe Fly
Eupraxia Pharmaceuticals reports Q1 net loss $6.8M vs. $6.2M last year
4M ago
EPRX
Eupraxia Pharmaceuticals Reports Q1 2025 Financial Results
PremiumCompany Announcements
Eupraxia Pharmaceuticals Reports Q1 2025 Financial Results
4M ago
6K
EPRX
Eupraxia Pharmaceuticals Reports Positive Nine-Month Outcomes in EoE Trial
PremiumCompany AnnouncementsEupraxia Pharmaceuticals Reports Positive Nine-Month Outcomes in EoE Trial
4M ago
EPRX
Eupraxia Pharmaceuticals announces treatment outcomes for EP-104GI
Premium
The Fly
Eupraxia Pharmaceuticals announces treatment outcomes for EP-104GI
4M ago
EPRX
Eupraxia Pharmaceuticals to Showcase Clinical Advances at April and May Conferences
Premium
Company Announcements
Eupraxia Pharmaceuticals to Showcase Clinical Advances at April and May Conferences
5M ago
6K
EPRX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >